AI Article Synopsis
- Cardiomyopathies are different heart disorders that can happen for various reasons and have different effects on people.
- Fibrosis, which is the thickening and scarring of heart tissue, is a common feature in these disorders and is linked to changes in the heart's structure.
- The study talks about how understanding these changes can help in diagnosing and treating heart problems better, and it suggests that special treatments targeting these changes could lead to more personalized care for patients.
Article Abstract
Cardiomyopathies encompass a spectrum of heart disorders with diverse causes and presentations. Fibrosis stands out as a shared hallmark among various cardiomyopathies, reflecting a common thread in their pathogenesis. This prevalent fibrotic response is intricately linked to the consequences of dysregulated extracellular matrix (ECM) remodeling, emphasizing its significance in the development and progression the disease. This review explores the ECM involvement in various cardiomyopathies and its impact on myocardial stiffness and fibrosis. Additionally, we discuss the potential of ECM fragments as early diagnosis, prognosis, and risk stratification. Biomarkers deriving from turnover of collagens and other ECM proteins hold promise in clinical applications. We outline current clinical management, future directions, and the potential for personalized ECM-targeted therapies with specific focus on microRNAs. In summary, this review examines the role of the fibrosis in cardiomyopathies, highlighting the potential of ECM-derived biomarkers in improving disease management with implications for precision medicine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.matbio.2024.02.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!